Medicenna Therapeutics (TSE:MDNA) Trading Down 2.1% – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price fell 2.1% during trading on Tuesday . The stock traded as low as C$0.45 and last traded at C$0.46. Approximately 16,293 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 91,649 shares. The stock had previously closed at C$0.47.

Medicenna Therapeutics Trading Down 2.1%

The business’s 50-day moving average price is C$0.40 and its two-hundred day moving average price is C$0.53. The company has a market capitalization of C$42.46 million, a P/E ratio of -2.09 and a beta of 3.00. The company has a debt-to-equity ratio of 6.22, a current ratio of 1.25 and a quick ratio of 4.65.

Medicenna Therapeutics (TSE:MDNA) last released its quarterly earnings data on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 360.29%. As a group, analysts forecast that Medicenna Therapeutics Corp. will post -0.37 EPS for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.